DCVC Bio reposted this
At Creyon, we're transforming nucleic acid drug discovery through our pioneering work on Oligonucleotide-Based Medicines (OBMs). While OBMs like ASOs and siRNAs can precisely target genetic diseases, addressing off-target effects is crucial and traditional genome-wide methods have been limited in scope and accuracy. Our latest research introduces DoReSeq, a technique to quantify off-target transcriptome-wide effects in OBMs with high accuracy and confidence scores. DoReSeq enables us to engineer more precise and effective OBM therapeutics and helps us unlock the full potential of these medicines. This is a significant step in our efforts to transform nucleic acid drug discovery to drug engineering, moving beyond failure prone trial-and-error processes for optimizing safety and efficacy. Read more in our latest research, featured in a preprint publication in bioRxiv & medRxiv: https://lnkd.in/e9mb3_Us
